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NUB1LThe Nobel prize has been awarded for the discovery of ubiquitin as a transferable signal for the degradation of
proteins by the 26S proteasome. While isopeptide linkage of a protein with a single ubiquitin does not serve
as a degradation signal for the proteasome, poly-ubiquitylation via several different lysine residues within
ubiquitin leads to efﬁcient proteasomal degradation. Ubiquitin-like modiﬁers have not been shown to directly
mediate proteasomal degradation except for the cytokine inducible modiﬁer HLA-F adjacent transcript 10
(FAT10), which consists of two ubiquitin-like domains. FAT10 ends with a free diglycine motif at its
C-terminus which is required for isopeptide linkage to hundreds of different substrates. In contrast to ubiquitin,
a single FAT10 sufﬁces to bind to the 26S proteasome and to efﬁciently mediate proteasomal degradation in a
ubiquitin-independent manner. Here we review the data on ubiquitin-independent degradation by FAT10, on
how FAT10 is conjugated to its substrates, how FAT10 binds to the 26S proteasome, and how the
ubiquitin-like (UBL)–ubiquitin-associated (UBA) protein NUB1L accelerates FAT10mediated proteolysis. Finally,
with a glimpse on recently identiﬁed substrates, wewill discuss the currently emerging knowledge about the bi-
ological functions of FAT10. This article is part of a Special Issue entitled:Ubiquitin-ProteasomeSystem.Guest Ed-
itors: Thomas Sommer and Dieter H. Wolf.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The ‘ubiquitin-proteasome system’ (UPS) is in charge of the degra-
dation of most short lived and long lived proteins outside the lysosome.
Since neither the central proteolytic unit of the UPS, the cylindrical 20S
proteasome, nor the 26S proteasomedegrades unmodiﬁed proteins to a
signiﬁcant degree, protein substrates of the UPS need to be modiﬁed
with a transferable signal in order to enable tight proteasome binding
and targeting for degradation. The impressive discovery of the post-
translational modiﬁcation of proteins with ubiquitin as a small protein
tag which enables proteasomal degradation was honored with the
Nobel prize for Avram Hershko, Aaron Ciechanover, and Erwin Rose in
2004 [1,2]. Ubiquitin becomes isopeptide linked to lysine residueswith-
in substrates and this requires the activation of ubiquitin at its
C-terminal diglycine residue by one of the two E1 type enzymes UBE1
[3] and UBA6 [4–7]. The activated ubiquitin can then be transferred
onto dozens of different E2 type enzymes which will be brought in
close contact with substrates by hundreds of different E3 ligases to en-
able their ubiquitylation usually on lysine residues [8,9]. While many of
the UPS substrates are short lived, ubiquitin itself is fairly long liveditin-Proteasome System. Guest
partment of Biology, University
any. Tel.: +49 7531 88 2130;
(M. Groettrup).
rights reserved.with an approximate half-life of 9 h [10,11] because it is removed
from its substrates by de-ubiquitylating enzymeswithin the 19S regula-
tor of the 26S proteasome before the substrate gets degraded [12].
Therefore ubiquitin can be reused for further degradation cycles and is
metabolically stable.
An important paradigm of the UPS system is that modiﬁcation of a
substrate protein with a single ubiquitin is not enough to mediate deg-
radation by the 26S proteasome. Ubiquitin chains have to be assembled
upon the substrate, or transferred as preformed chains, which need to
contain four ubiquitin molecules or more [13]. Ubiquitin contains 7
lysines (at positions 6, 11, 27, 29, 33, 48, and 63) all of which can them-
selves become ubiquitylated to form poly-ubiquitin chains and all these
linkages contribute to proteasomal degradation with the apparent
exception of K63 [14]. The reason for the need to assemble poly-
ubiquitin chains for proteasomal targeting is probably that a single
ubiquitin binds with insufﬁcient afﬁnity to the validated ubiquitin
receptors within the 19S regulator of the 26S proteasome which are
S5a (RPN10) [15] and ARM1 (RPN13) [16].
In this articlewe review the current knowledge on a second transfer-
able signal for degradation by the proteasome named FAT10. The inter-
est in research on FAT10 is steadily increasing because it is the only
ubiquitin-likemodiﬁerwhich directly targets its substrates for degrada-
tion by the 26S proteasome. The modiﬁcation of substrates with the
modiﬁer SUMO-2/3 can lead to recognition and poly-ubiquitylation by
the ubiquitin E3 ligase RNF4 and, as a consequence of this secondary
poly-ubiquitylation, to degradation by the proteasome [17–19]. FAT10,
in contrast, directly binds to the proteasome and according to our data
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degradation tag [20–22]. However, this conception has recently been
challenged [23] and we will review the data which support and which
question this notion. In addition, we will outline in which respects
FAT10 differs from ubiquitin as a degradation signal (Fig. 1), how
FAT10 is conjugated to substrates, and ﬁnally we will surface what
these substrates are andwhat theymay tell us about the biological func-
tion of FAT10. In a nutshell: we will review the ‘FAT10-proteasome
system’ (FPS).
2. The FAT10 facts paragraph
‘FAT10’ is an abbreviation for Human Leukocyte Antigen (HLA)-F ad-
jacent transcript 10 as the FAT10 open reading frame consisting of two
ubiquitin-like domains in tandemarraywas discovered during genomic
sequencing of the human major histocompatibility complex (MHC) by
Sherman Weissman and colleagues in 1996 [24]. FAT10 was initially
named ‘diubiquitin’ or ‘ubiquitin D’ but these names are not in frequent
use any longer. The twoN- and C-terminal ubiquitin-like domains of the
18 kD FAT10 protein are 29% and 36% identical to ubiquitin. The FAT10
protein endswith a free GGmotif which is immediately available for ac-
tivation and conjugation in contrast to ubiquitin and other modiﬁers
which need to be C-terminally processed from precursor proteins in
order to act as modiﬁers. The high resolution three-dimensional struc-
ture of FAT10 has not been reported to date, most likely because
FAT10 is poorly soluble at higher concentrations, both when produced
in Escherichia coli or mammalian expression systems, but structure pre-
dictions hold that FAT10 folds quite similarly to ISG15 [25] with two
typical β-grasp fold domains connected by a short linker [7].
In contrast to ubiquitin, which – as its name tells - is ubiquitously
expressed, FAT10 expression is largely restricted to tissues of the immune
system like thymus, lymph nodes and spleen in the human and mouse
[26–28]. However, under stimulation with the pro-inﬂammatory cyto-
kines interferon (IFN)-γ and tumor necrosis factor (TNF)-α, FAT10 is
strongly and synergistically induced onmRNA and protein level in virtu-
ally all tissues [29,30]. A synergismbetween IFN-γ and TNF-α is observed
with several MHC encoded genes but it is especially pronounced forFig. 1. Differences between ubiquitin aFAT10.We recently investigated the kinetics of FAT10mRNA and protein
induction following the stimulation of the human embryonic kidney cell
line HEK293with IFN-γ and TNF-α and found that while FAT10mRNA is
already detectable by qRT-PCR2–3 h after induction [29] higher amounts
of FAT10mRNA and FAT10 protein are only detected 24 h after induction
[31]. Moreover, FAT10 is induced during thematuration of dendritic cells
triggered by different toll-like receptor ligands [27,32] which enhances
their potential to present antigens and to stimulate T cells. Taken to-
gether, the localization of the FAT10 gene in the MHC locus, the tissue
expression proﬁle, the cytokine inducibility, and the up-regulation in
mature dendritic cells all point at a function of FAT10 in the immune
system. Consistent with a function of FAT10 in the immune system is
the very mild phenotype of FAT10 knockout mice kept under speciﬁc
pathogen free conditions. Only when these mice were systemically
treated with a sublethal dose of lipopolysaccharide, an endotoxin hy-
persensitivity phenotype became apparent [28]. However, while most
genes involved in the adaptive immune response evolved with sharks
and bony ﬁsh, FAT10 has only been detected in mammals [7] arguing
for a more specialized function in the immune defense as for instance
the response to a certain group of mammalian pathogens.
3. The E1 and E2 enzymes of the FAT10 conjugation cascade
It is a hallmark of ubiquitin-like modiﬁers like SUMO, NEDD8, or
ISG15 that their activation and transfer onto substrates are mediated
by ‘private’ cascades of E1, E2, and E3 enzymes. The E1 enzyme of
FAT10 conjugation, designated UBA6 (MOP-4, E1L2, and UBE1L2), in
contrast, activates both ubiquitin and FAT10 [4–7]. While FAT10
binds to UBA6 with higher afﬁnity than ubiquitin, the adenylation
and transthiolation reaction is much slower for FAT10 than for
ubiquitin [33]. The activation of FAT10 by UBA6 and the formation
of a UBA6–FAT10 thioester have been shown in vitro. SiRNAmediated
silencing of UBA6 expression interferes with the formation of FAT10
conjugates in HEK293 cells, indicating that no other E1 type enzymes
activate FAT10 [6,34]. Interestingly, also the E2 enzyme in charge of
FAT10 conjugation is bi-speciﬁc for ubiquitin and FAT10. This en-
zyme, ﬁrst named UBE2Z [35] and then renamed to ‘UBA6 speciﬁcnd FAT10 as degradation signals.
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cept activated ubiquitin exclusively from UBA6 but not from UBE1.
USE1 was shown to interact with FAT10 in yeast two hybrid assays
and forms a thioester with FAT10 in vitro [34]. The knock down of
USE1 interferes with the formation of bulk FAT10 conjugates both
under endogenous and overexpression conditions, suggesting that
USE1 is the main if not the only E2 enzyme for FAT10. Remarkably,
USE1 auto-FAT10ylates itself in cis i.e. it transfers the thioester-
linked FAT10 onto one of its lysines to form a stable isopeptide link-
age both in vitro and in intact cells which renders USE1 both an E2
enzyme and a substrate of FAT10ylation [34]. It will be interesting
to study the structural and functional consequences of this quite efﬁ-
cient auto-FAT10ylation of USE1.
Not yet discovered have been the putative E3 ligases and de-
conjugating enzymes of the FAT10 cascade. While E3 enzymes are
probably required to allow substrate speciﬁc FAT10ylations, it is less
clear whether de-FAT10ylating enzymes exist at all. We have shown
in HEK293 and HeLa cells, both before and after IFN-γ stimulation,
that while linear ubiquitin–GFP fusions are rapidly cleaved by de-
ubiquitylating enzymes, FAT10–GFP fusions are not [20]. This does not
exclude that de-FAT10ylating enzymes may be expressed elsewhere
e.g. in certain cell types of the immune system. Moreover, the assump-
tion that a putative de-FAT10ylating enzyme is able to cleave linear
FAT10-fusion proteins may not be valid. However, FAT10 – in contrast
to othermodiﬁers – does not need to be liberated from C-terminally ex-
tended precursors. In contrast to the fairly long lived ubiquitin, which is
readily removed from substrates at the 26S proteasome before degrada-
tion, pulse chase experimentswith a so far unidentiﬁed FAT10 substrate
have not provided any evidence for a de-FAT10ylation reaction. Rather,
the FAT10-conjugated substrate was degraded at the same rate as
FAT10 itself with a half-life of approx. 1 h [20]. It is therefore quite pos-
sible that FAT10 is not de-conjugated at the 26S proteasome but instead
degraded along with its substrate.
4. FAT10 as a transferable signal for degradation by the
26S proteasome
The ﬁrst evidence that FAT10 and FAT10 conjugates are degraded by
the proteasome emerged from the observation that they accumulated
when the proteasome was inhibited [36]. Next it was shown that the
N-terminal fusion of FAT10 to long lived proteins like green ﬂuorescent
protein (GFP), dihydrofolate reductase (DHFR) or the nucleoprotein of
Lymphocytic Choriomeningitis Virus (LCMV) reduced their half-lives
as potently as fusion with ubiquitin did, while fusion of SUMO1 to GFP
did not have such an effect [20,37]. Recently, we have shown that a
natural, isopeptide linked substrate of FAT10 conjugation in cytokine
treated HEK293 cells i.e. the autophagy adaptor p62/Sequestosome-1,
strongly accumulated under proteasome inhibition in cycloheximide
chase experiments, while the unconjugated p62 protein did not [31].
Moreover, fusions of FAT10 to the LCMV nucleoprotein or the human
cytomegalovirus derived protein pp65 enhanced their presentation
along the proteasome dependent MHC class I presentation pathway
[37,38].
Another line of evidence that FAT10 targets substrates to the
proteasome emerged from the identiﬁcation of the ubiquitin-like
(UBL)/ubiquitin-associated (UBA) domain protein NEDD8 ultimate
buster-1 long (NUB1L) [39] as a non-covalent interaction partner of
FAT10. The coexpression of the likewise interferon inducible protein
NUB1L [40] accelerated the degradation of FAT10 by the proteasome
approx. fourfold. NUB1L binds to the proteasome via its N-terminal
UBL domain and to FAT10 via its three C-terminal UBA domains
suggesting that it may serve as a linker between the proteasome
and FAT10 [41]. However, subsequently it was found that even a
ΔUBA deletion variant of NUB1L was able to accelerate FAT10 degra-
dation while the deletion of the UBL domain of NUB1L abolished
this effect. Moreover, we found that FAT10 itself can bind to theproteasome in the absence of NUB1L. Therefore, we postulated that
docking of the UBL domain of NUB1L to the 26S proteasome would
‘facilitate’ the degradation of FAT10 by the proteasome [42] as it
had been similarly postulated for RPN10 in the ubiquitin system
[43] (Fig. 2). These interesting ﬁndings raised the question how
and to which subunit FAT10 binds at the 26S proteasome and
how NUB1L accelerates its degradation. We recently identiﬁed the
ubiquitin receptor RPN10 (S5a) as the subunit of the 26S proteasome
where FAT10 binds while NUB1L can bind both to RPN10 as well as
the 19S regulator subunit RPN1 (S2) [22,44]. Surprisingly, neither
FAT10 nor NUB1L bound to the two C-terminal ubiquitin interacting
motifs (UIM) of RPN10, where poly-ubiquitin chains bind, but to the
N-terminal von Willebrand A (VWA) domain of RPN10 which ap-
pears to be a novel docking site for ubiquitin-like proteins. In order
to investigate whether this interaction with the VWA domain of
RPN10 is functionally important, we reconstituted the NUB1L depen-
dent FAT10 degradation in S. cerevisiae which survives the deletion
of rpn10. We found that FAT10 degradation and its acceleration by
NUB1L could be reconstituted in rpn10-deﬁcient yeast just by ex-
pressing the VWA domain of RPN10 alone, thus demonstrating its
functional relevance [22].
5. FAT10 — a ubiquitin independent signal for degradation by the
proteasome: the Pros and Cons
It is an important question whether FAT10 can target substrate pro-
teins to the proteasome independently of poly-ubiquitylation of FAT10
or whether it relies on secondary poly-ubiquitylation as has been
shown for SUMO [17–19]. The ﬁnding that FAT10 directly interacts
with the VWA domain of RPN10 [22] suggests that at least for binding
to the proteasome no ubiquitylation is required. Apparently the two
ubiquitin-like domains of FAT10 are sufﬁcient for this interaction while
ubiquitin requires four or more units to efﬁciently mediate degradation
by theproteasome [13].Wehave investigated the ubiquitin-dependence
of FAT10-mediated degradation by the proteasome with three ap-
proaches [20].
1) All 17 lysines within FAT10 were mutated to arginines (an amino
acid that cannot be ubiquitylated), which completely eliminated
the marked mono-ubiquitylation and weak poly-ubiquitylation
of FAT10 in HEK293 cells. In radioactive pulse-chase experiments
wt and lysine-deﬁcient (K0) FAT10 were degraded at the same
rate and coexpression of NUB1L accelerated this proteasome
dependent degradation even more as compared to wt FAT10,
strongly suggesting that ubiquitylation of FAT10 was not re-
quired. The same conclusion was also reached when the degrada-
tion of wt FAT10 and FAT10-K0 was monitored in cycloheximide
chase experiments in Saccharomyces cerevisiae [22].
2) The degradation of a FAT10–GFP fusion proteinwasmonitored after
radioactive pulse labeling over a time period of 5 h in the UBE1 tem-
perature sensitive mutant E36-ts20 and the UBE1 reconstituted
transfectant E36-ts20/E1 at the restrictive temperature. The degra-
dation of FAT10–GFP was not changed after inactivation of the
ubiquitin activating enzyme UBE1 while the ubiquitin-dependent
degradation of the N-end rule substrate Arg-β-galactosidase was
arrested under the same conditions. While both aforementioned
experiments in cells were strongly suggestive for an ubiquitin
independent FAT10-mediated degradation, a third experiment was
performed in vitro which we consider the most conclusive.
3) A radiolabeled FAT10–DHFR fusion protein was incubated with
highly puriﬁed 26S proteasome and the degradation was moni-
tored in the presence and absence of puriﬁed recombinant
NUB1L. It was shown that FAT10–DHFR was efﬁciently degraded
by the 26S but not the 20S proteasome and the degradation was
promoted by NUB1L in a dose dependent manner [21]. Because
the generation of acid soluble radioactivity was used to measure
Fig. 2. The 26S proteasome subunit Rpn10 (S5a) as a docking site for FAT10, NUB1L, and poly-ubiquitin. FAT10 binds with its C-terminal ubiquitin-like (UBL) domain to the von
Willebrand A (VWA) domain of Rpn10 and with its N-terminal UBL domain to the ubiquitin-associated (UBA) domains of NUB1L. NUB1L, in turn, binds with is N-terminal UBL
domain to the VWA domain of Rpn10. Therefore FAT10 can dock to the 26S proteasome either directly or via NUB1L. Lysine 48-linked poly-ubiquitin chains, in contrast, bind to
the ubiquitin interaction motifs (UIM) 1 and 2 of Rpn10.
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account for this result. Since in the same experiment a radiolabeled
ubiquitin–DHFR fusion protein was not degraded we could be sure
that no contaminating poly-ubiquitylation enzymes were present
because otherwise ubiquitin–DHFR would have been further
ubiquitylated and degraded by the 26S proteasome.
The concept that FAT10 functions as a degradation tag indepen-
dently of poly-ubiquitylation has recently been called into question
by a study by A. Ciechanover and colleagues which reports that
ubiquitylation of FAT10 enhances the rate of FAT10-mediated degra-
dation [23]. These authors also performed a pulse chase experiment
in HEK293 cells with wt FAT10 and a lysine-deﬁcient K0 mutant of
FAT10 but they ascribe the diminution of the FAT10-K0 protein
over time to progressive precipitation of this protein rather than
degradation by the proteasome. We agree with Buchsbaum et al.
that uponmassive (but not moderate) overexpression the K0mutant
has a slightly higher tendency to precipitate than wt FAT10. Howev-
er, precipitation is unlikely to contribute to the loss of signal of the
soluble FAT10 or FAT10 KO in our system. As proteasome inhibition,
which usually promotes protein aggregation in cells, blocked degra-
dation of soluble FAT10-K0, we very likely monitored degradation by
the proteasome rather than precipitation. Evenmore compelling, the
coexpression of NUB1L in our experiments strongly accelerated the
degradation of FAT10-K0 again arguing in favor of proteasomal deg-
radation. In their discussion Buchsbaum et al. agree with us that
binding of FAT10 is sufﬁcient to promote the proteasomal degrada-
tion. What has remained controversial is whether ubiquitylation of
FAT10 is able to accelerate FAT10-mediated protein destruction or
not. Further experiment will hopefully settle this remaining issue.
6. The substrates of FAT10 conjugation — some clues to
FAT10 biology
While considerable progress has been made throughout the past
years with respect to the activation and conjugation of FAT10 and
proteasome targeting via FAT10, the biological function of FAT10 is still
poorly understood. The inapparent phenotype of FAT10−/− mice kept
under speciﬁc pathogen free conditions suggests that the phenotype
will only become visible after infection with a certain pathogen which
induces an IFN-γ/TNF-α response and maturation of dendritic cells and
by this means switches on FAT10 expression. However, overexpressionof FAT10 has been shown to induce apoptosis in mouse ﬁbroblasts
[36], HeLa cells [30], and renal tubular epithelial cells [45]. The mecha-
nism of apoptosis induction by FAT10 is not clear but it does not seem
to be a mere overexpression artefact since immortalized human proxi-
mal tubular cells which had been infected with HIV-1 in vitro were
protected from apoptosis when FAT10 expression was knocked down
[45]. A role for FAT10 in the induction of apoptosis would be consistent
with its inducibility by the pro-apoptotic cytokines IFN-γ and TNF-α. Re-
cently, it has been shown that the inﬂammatory mediator leucine-rich
repeat Fli-I-interacting protein 2 (LRRFIP2), which is a positive regulator
of NF-kB activity in the toll-like receptor (TLR)4-mediated inﬂammatory
response, is covalently modiﬁed by FAT10 [46]. FAT10ylation of LRRFIP2
hinders its recruitment to the membrane leading to an inhibition of
LPS/TLR4 mediated NF-kB activation. Since NF-kB activation tran-
scriptionally induces apoptosis inhibitors, this ﬁnding may explain
why the overexpression of FAT10 can induce apoptosis and why
FAT10−/− mice are hypersensitive to LPS challenge [28]. However,
when spontaneous apoptosis was monitored in leukocytes from
spleen, thymus and bone marrow of FAT10-deﬁcient versus wt
mice, FAT10 seemed to protect these cells from apoptosis rather
than inducing it [28]. Moreover, the colon cancer cell line HCT116
was partially protected from TNF-α induced apoptosis in the pres-
ence of FAT10 [47]. It is possible that an apoptosis modulating func-
tion of FAT10 is cell type speciﬁc but the mechanisms involved have
remained elusive and further investigations are warranted.
A second hint towards FAT10 function stems from the identiﬁcation
of the spindle assembly checkpoint protein MAD2 as a non-covalent
binding partner of FAT10 [30]. Overexpression of FAT10 in HCT116
cells reduced the localization of MAD2 at the kinetochore during
prometaphase and resulted in a missegregation of chromosomes after
100 cell divisions [47]. Conversely, TNF-α induced effects in the same
cell line like the delocalization of MAD2 from kinetochores, acceleration
of mitosis, and the missegregation of chromosomes were all abolished
when FAT10was knocked down [48]. An inﬁdelity of chromosome seg-
regation during mitosis is a hallmark of cancer cells and it is therefore
striking that FAT10 was found to be highly overexpressed in hepatocel-
lular, colorectal, ovarial, and uterus carcinomawhich led to the proposal
that FAT10 expression may promote oncogenesis [26]. However, we
found that 72% of the analyzed hepatocellular carcinoma and 53% of
colon carcinoma tissues, which overexpressed FAT10, also expressed
the IFN-γ/TNF-α-dependent immunoproteasome subunit LMP2. This
suggested that FAT10 overexpression in carcinoma tissues may be a
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cer samples rather than an indicator that FAT10 is oncogenic [27]. In
support of this notion, FAT10was found to be expressed in hepatocellu-
lar carcinoma cells in a chemically inducedmousemodel for liver cancer
but aberrations of chromosomenumbers in these cells could not be con-
ﬁrmed [49].
In order to gain better mechanistic insights into these and other
proposed functions of FAT10, it is important to identify the substrates
of FAT10 conjugation as well as further non-covalent interaction part-
ners of FAT10. The overexpression of wt FAT10 but not a ΔGG mutant
of FAT10 in HEK293 cells resulted in the formation of a high molecu-
lar weight smear of FAT10 conjugates which looked similar to classi-
cal ubiquitin smears [6,34]. Using a high afﬁnity monoclonal antibody
to human FAT10, designated 4F1, we could conﬁrm the formation of
such FAT10 smears also under endogenous conditions in IFN-γ/
TNF-α stimulated HEK293 cells [34]. We have recently used this anti-
body to immunopurify endogenous FAT10 substrates and interaction
partners from IFN-γ/TNF-α stimulated HEK293 cells and identiﬁed
569 FAT10 binding proteins by mass spectrometric analysis, none of
which were detected in unstimulated HEK293 cells [31]. Of these
569 proteins, 169 were scored as putative covalent FAT10 conjugation
substrates based on their apparent molecular mass being at least
18 kDa (i.e. the molecular weight of FAT10) higher than their predict-
ed molecular mass. 14/15 of these proteins have been conﬁrmed to be
FAT10 conjugates by combined immunoprecipitation/western blot-
ting experiments in our laboratory to date. We had hoped that the pu-
tative FAT10 conjugates would belong to one or at least a few cell
biological pathways, which could have directed the focus of FAT10 re-
search onto such a pathway. However, similarly to the hundreds of
conjugates of ubiquitin, SUMO, or ISG15, also the many putative
and conﬁrmed substrates of FAT10 conjugation must be assigned to
many different areas of cell biology and do not provide such a clue.
Therefore, we ﬁrst focused on one interesting FAT10 conjugate,
the autophagy adaptor p62/sequestosome-1. We were especially fas-
cinated by this protein because we had shown before that FAT10, just
like ubiquitin, is transported by histone deacetlyase 6 along microtu-
bules into juxtanuclear protein aggregates called ‘aggresomes’ when
proteasome activity is inhibited in cells [50]. P62, which is also local-
ized in aggresomes as well as protein aggregates of neuronal protein
aggregation diseases, binds non-covalently to ubiquitin as well as to
FAT10 but it is also a substrate of FAT10ylation under overexpression
and endogenous conditions. We were expecting that p62, which
binds to LC3 proteins involved in autophagosome formation, would
target FAT10 in aggresomes for degradation in autophagolysosomes,
but so far no evidence for degradation of FAT10 and its conjugates in
acidifying autophagosomes could be obtained [31]. Based on these
ﬁrst data it appears that FAT10, in contrast to ubiquitin, does not
target for autophagic but only for proteasomal degradation.
7. The ‘FAT10 proteasome system’ (FPS) — concluding remarks
and outlook
Although the number of groups investigating FAT10 is constantly in-
creasing, FAT10 research is still in an early stage especially with respect
to understanding the biological consequences of FAT10ylation, but also
with respect to the control of FAT10 conjugation. It is an intriguing
question how the E1 and E2 enzymes UBA6 and USE1, which both are
bispeciﬁc for ubiquitin and FAT10, discriminate which substrates are
to be ubiquitylated andwhich substrates are to be FAT10ylated. The pu-
tative E3 enzymes of FAT10ylation, which remain to be identiﬁed, may
offer a solution to this enigma. It is doubtful whether de-FAT10ylating
enzymes exist, but if they do theywould be worthwhile to be identiﬁed
as well, given that deubiquitylating enzymes are very actively pursued
as drug targets in the pharmaceutical industry these days and given
that a number of putative FAT10 targets are oncogenes or apoptosis in-
hibitors. The most burning question, however, is why has the FAT10Proteasome System (FPS) evolved so late? Why is it cytokine inducible
and why is it apparently irreversible? Our perhaps biased opinion fol-
lows FAT10's chromosomal localization in the MHC locus and its tissue
expression proﬁle in thymus, lymph nodes and spleen: FAT10 is the im-
mune system's back up for ubiquitin.
Acknowledgements
We thank Kay Diederichs for help with ﬁgure preparations. This
work was supported by the German Research Foundation (DFG)
grants GR1517/2-4 and GR1517/13-1, the Konstanz Graduate School
Chemical Biology, the Research Training Group 1331, and the DFG
Collaborative Research Center SFB969, Project C01.
References
[1] A. Ciechanover, Y. Hod, A. Hershko, A heat-stable polypeptide component of an
ATP-dependent proteolytic system from reticulocytes, Biochem. Biophys. Res.
Commun. 81 (1978) 1100–1105.
[2] A. Hershko, A. Ciechanover, A. Varshavsky, The ubiquitin system, Nat. Med. 6
(2000) 1073–1081.
[3] A. Ciechanover, H. Heller, R. Katz-Etzion, A. Hershko, Activation of the heat-stable
polypeptide of the ATP-dependent proteolytic system, Proc. Natl. Acad. Sci. U. S.
A. 78 (1981) 761–765.
[4] C. Pelzer, I. Kassner, K. Matentzoglu, R.K. Singh, H.P. Wollscheid, M. Scheffner,
G. Schmidtke, M. Groettrup, UBE1L2, a novel E1 enzyme speciﬁc for ubiquitin,
J. Biol. Chem. 282 (2007) 23010–23014.
[5] J.P. Jin, X. Li, S.P. Gygi, J.W. Harper, Dual E1 activation systems for ubiquitin differ-
entially regulate E2 enzyme charging, Nature 447 (2007) 1135–1137.
[6] Y.H. Chiu, Q. Sun, Z.J. Chen, E1-L2 activates both ubiquitin and FAT10, Mol. Cell 27
(2007) 1014–1023.
[7] M. Groettrup, C. Pelzer, G. Schmidtke, K. Hofmann, Activating the ubiquitin family:
UBA6 challenges the ﬁeld, Trends Biochem. Sci. 33 (2008) 230–237.
[8] D. Finley, Recognition and processing of ubiquitin-protein conjugates by the
proteasome, Annu. Rev. Biochem. 78 (2009) 477–513.
[9] O. Kerscher, R. Felberbaum, M. Hochstrasser, Modiﬁcation of proteins by ubiquitin
and ubiquitin-like proteins, Annu. Rev. Cell Dev. Biol. 22 (2006) 159–180.
[10] N. Carlson, M. Rechsteiner, Microinjection of ubiquitin: intracellular distribution
and metabolism in HeLa cells maintained under normal physiological conditions,
J. Cell Biol. 104 (1987) 537–546.
[11] Y. Hiroi, M. Rechsteiner, Ubiquitin metabolism in HeLa cells starved of amino
acids, FEBS Lett. 307 (1992) 156–161.
[12] K.D. Wilkinson, DUBs at a glance, J. Cell Sci. 122 (2009) 2325–2329.
[13] J.S. Thrower, L. Hoffman,M. Rechsteiner, C.M. Pickart, Recognition of thepolyubiquitin
proteolytic signal, EMBO J. 19 (2000) 94–102.
[14] P. Xu, D.M. Duong, N.T. Seyfried, D.M. Cheng, Y. Xie, J. Robert, J. Rush, M.
Hochstrasser, D. Finley, J. Peng, Quantitative proteomics reveals the function of un-
conventional ubiquitin chains in proteasomal degradation, Cell 137 (2009) 133–145.
[15] Q. Deveraux, V. Ustrell, C. Pickart, M. Rechsteiner, A 26S protease subunit that
binds ubiquitin conjugates, J. Biol. Chem. 269 (1994) 7059–7061.
[16] K. Husnjak, S. Elsasser, N.X. Zhang, X. Chen, L. Randles, Y. Shi, K. Hofmann,
K.J. Walters, D. Finley, I. Dikic, Proteasome subunit Rpn13 is a novel ubiquitin recep-
tor, Nature 453 (2008) 481–488.
[17] M.H. Tatham, M.C. Geoffroy, L. Shen, A. Plechanovova, N. Hattersley, E.G. Jaffray,
J.J. Palvimo, R.T. Hay, RNF4 is a poly-SUMO-speciﬁc E3 ubiquitin ligase required
for arsenic-induced PML degradation, Nat. Cell Biol. 10 (2008) 538–546.
[18] V. LallemandBreitenbach, M. Jeanne, S. Benhenda, R. Nasr, M. Lei, L. Peres, J. Zhou,
J. Zhu, B. Raught, H. deThe, Arsenic degrades PML or PML-RAR alpha through
a SUMO-triggered RNF4/ubiquitin-mediated pathway, Nat. Cell Biol. 10 (2008)
547–555.
[19] S.R. Weisshaar, K. Keusekotten, A. Krause, C. Horst, H.M. Springer, K. Gottsche,
R.J. Dohmen, G.J. Praefcke, Arsenic trioxide stimulates SUMO-2/3 modiﬁcation
leading to RNF4-dependent proteolytic targeting of PML, FEBS Lett. 582 (2008)
3174–3178.
[20] M.S. Hipp, B. Kalveram, S. Raasi, M. Groettrup, G. Schmidtke, FAT10, a ubiquitin-
independent signal for proteasomal degradation, Mol. Cell. Biol. 25 (2005)
3483–3491.
[21] G. Schmidtke, B. Kalveram, M. Groettrup, Degradation of FAT10 by the 26S
proteasome is independent of ubiquitylation but relies on NUB1L, FEBS Lett.
583 (2009) 591–594.
[22] N. Rani, A. Aichem, G. Schmidtke, S.G. Kreft, M. Groettrup, FAT10 and NUB1L bind
to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteol-
ysis, Nat. Commun. 3 (2012) 749, http://dx.doi.org/10.1038/ncomms1752.
[23] S. Buchsbaum, B. Bercovich, A. Ciechanover, FAT10 is a proteasomal degradation
signal that is itself regulated by ubiquitination, Mol. Biol. Cell 23 (2012) 225–232.
[24] W. Fan, W. Cai, S. Parimoo, G.G. Lennon, S.M. Weissman, Identiﬁcation of seven
new human MHC class I region genes around the HLA-F locus, Immunogenetics
44 (1996) 97–103.
[25] J. Narasimhan, M. Wang, Z.J. Fu, J.M. Klein, A.L. Haas, J.J.P. Kim, Crystal structure
of the interferon-induced ubiquitin-like protein ISG15, J. Biol. Chem. 280 (2005)
27356–27365.
102 G. Schmidtke et al. / Biochimica et Biophysica Acta 1843 (2014) 97–102[26] C.G. Lee, J. Ren, I.S. Cheong, K.H. Ban, L.L. Ooi, S. Yong Tan, A. Kan, I. Nuchprayoon,
R. Jin, K.H. Lee, M. Choti, L.A. Lee, Expression of the FAT10 gene is highly
upregulated in hepatocellular carcinoma and other gastrointestinal and gyneco-
logical cancers, Oncogene 22 (2003) 2592–2603.
[27] S. Lukasiak, C. Schiller, P. Oehlschlaeger, G. Schmidtke, P. Krause, D.F. Legler, F.
Autschbach, P. Schirmacher, K. Breuhahn, M. Groettrup, Proinﬂammatory cyto-
kines cause FAT10 upregulation in cancers of liver and colon, Oncogene 27
(2008) 6068–6074.
[28] A. Canaan, X.F. Yu, C.J. Booth, J. Lian, I. Lazar, S.L. Gamﬁ, K. Castille, N. Kohya, Y.
Nakayama, Y.C. Liu, E. Eynon, R. Flavell, S.M. Weissman, FAT10/diubiquitin-like
protein-deﬁcient mice exhibit minimal phenotypic differences, Mol. Cell. Biol.
26 (2006) 5180–5189.
[29] S. Raasi, G. Schmidtke, R.d. Giuli, M. Groettrup, A ubiquitin-like protein which
is synergistically inducible by interferon-γ and tumor necrosis factor-α, Eur.
J. Immunol. 29 (1999) 4030–4036.
[30] Y. Liu, J. Pan, C. Zhang, W. Fan, M. Collinge, J.R. Bender, S.M. Weissman, A MHC-
encoded ubiquitin-like protein (FAT10) binds noncovalently to the spindle assembly
checkpoint protein MAD2, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4313–4318.
[31] A. Aichem, B. Kalveram, V. Spinnenhirn, K. Kluge, N. Catone, T. Johansen, M.
Groettrup, The proteomic analysis of FAT10 substrates identiﬁes p62/SQSTM1
as a substrate of FAT10ylation, J. Cell Sci. 125 (2012) 4576–4585.
[32] F. Ebstein, N. Lange, S. Urban, U. Seifert, E. Kruger, P.M. Kloetzel, Maturation
of human dendritic cells is accompanied by functional remodelling of the
ubiquitin-proteasome system, Int. J. Biochem. Cell Biol. 41 (2009) 1205–1215.
[33] J.M. Gavin, J.J. Chen, H. Liao, N. Rollins, X.F. Yang, Q. Xu, J.Y. Ma, H.K. Loke, T. Lingaraj, J.E.
Brownell, W.D. Mallender, A.E. Gould, B.S. Amidon, L.R. Dick, Mechanistic studies on
activation of ubiquitin and di-ubiquitin-like protein, FAT10, by ubiquitin-like modiﬁer
activating enzyme 6, Uba6, J. Biol. Chem. 287 (2012) 15512–15522.
[34] A. Aichem, C. Pelzer, S. Lukasiak, B. Kalveram, P.W. Sheppard, N. Rani, G.
Schmidtke, M. Groettrup, USE1 is a bispeciﬁc conjugating enzyme for ubiquitin
and FAT10, which FAT10ylates itself in cis, Nat. Commun. 1 (2010) 13.
[35] X. Gu, F. Zhao, M. Zheng, X. Fei, X. Chen, S. Huang, Y. Xie, Y. Mao, Cloning and char-
acterization of a gene encoding the human putative ubiquitin conjugating en-
zyme E2Z (UBE2Z), Mol. Biol. Rep. 34 (2007) 183–188.
[36] S. Raasi, G. Schmidtke, M. Groettrup, The ubiquitin-like protein FAT10 forms co-
valent conjugates and induces apoptosis, J. Biol. Chem. 276 (2001) 35334–35343.
[37] C. Schliehe, A. Bitzer, M. van den Broek, M. Groettrup, Stable antigen is most effec-
tive for eliciting CD8+ T-cell responses after DNA vaccination and infection with
recombinant vaccinia virus in vivo, J. Virol. 86 (2012) 9782–9793.[38] F. Ebstein, A. Lehmann, P.M. Kloetzel, The FAT10- and ubiquitin-dependent deg-
radation machineries exhibit common and distinct requirements for MHC class
I antigen presentation, Cell. Mol. Life Sci. 69 (2012) 2443–2454.
[39] T. Kamitani, K. Kito, T. Fukuda-Kamitani, E.T.H. Yeh, Targeting of NEDD8 and its
conjugates for proteasomal degradation by NUB1, J. Biol. Chem. 276 (2001)
46655–46660.
[40] K. Kito, E.T.H. Yeh, T. Kamitani, NUB1, a NEDD8-interacting protein, is induced by
interferon and down-regulates the NEDD8 expression, J. Biol. Chem. 276 (2001)
20603–20609.
[41] M.S. Hipp, S. Raasi, M. Groettrup, G. Schmidtke, NEDD8 ultimate buster-1L
interacts with the ubiquitin-like protein FAT10 and accelerates its degradation,
J. Biol. Chem. 279 (2004) 16503–16510.
[42] G. Schmidtke, B. Kalveram, E. Weber, P. Bochtler, S. Lukasiak, M.S. Hipp, M.
Groettrup, The UBA domains of NUB1L are required for binding but not for accel-
erated degradation of the ubiquitin-like modiﬁer FAT10, J. Biol. Chem. 281 (2006)
20045–20054.
[43] R. Verma, R. Oania, J. Graumann, R.J. Deshaies, Multiubiquitin chain receptors de-
ﬁne a layer of substrate selectivity in the ubiquitin-proteasome system, Cell 118
(2004) 99–110.
[44] K. Tanji, T. Tanaka, T. Kamitani, Interaction of NUB1 with the proteasome subunit
S5a, Biochem. Biophys. Res. Commun. 337 (2005) 116–120.
[45] M.J. Ross, M.S. Wosnitzer, M.D. Ross, B. Granelli, G.L. Gusella, M. Husain, L.
Kaufman, M. Vasievich, V.D. D'Agati, P.D. Wilson, M.E. Klotman, P.E. Klotman,
Role of ubiquitin-like protein FAT10 in epithelial apoptosis in renal disease,
J. Am. Soc. Nephrol. 17 (2006) 996–1004.
[46] S. Buchsbaum, B. Bercovich, T. Ziv, A. Ciechanover, Modiﬁcation of the inﬂamma-
tory mediator LRRFIP2 by the ubiquitin-like protein FAT10 inhibits its activity
during cellular responses to LPS, Biochem. Biophys. Res. Com. 428 (2012) 11–16.
[47] J.W. Ren, A. Kan, S.H. Leong, L.L.P.J. Ooi, K.T. Jeang, S.S. Chong, O.L. Kon, C.G.L. Lee,
FAT10 plays a role in the regulation of chromosomal stability, J. Biol. Chem. 281
(2006) 11413–11421.
[48] J.W. Ren, Y. Wang, Y. Gao, S.B.K. Mehta, C.G.L. Lee, FAT10 mediates the effect of
TNF-alpha in inducing chromosomal instability, J. Cell Sci. 124 (2011) 3665–3675.
[49] J. Oliva, F. BardagGorce, B.A. French, J. Li, L. McPhaul, F. Amidi, J. Dedes, A. Habibi, S.
Nguyen, S.W. French, Fat10 is an epigenetic marker for liver preneoplasia in a
drug-primed mouse model of tumorigenesis, Exp. Mol. Pathol. 84 (2008) 102–112.
[50] B. Kalveram, G. Schmidtke, M. Groettrup, The ubiquitin-like modiﬁer FAT10 inter-
acts with HDAC6 and localizes to aggresomes under proteasome inhibition, J. Cell
Sci. 121 (2008) 4079–4088.
